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Summary  Until  2010,  Japan  had  been  using  the  Toyobo  (Nipro,  Osaka,  Japan)  extracorporeal
left ventricular  assist  device  (VAD)  developed  30  years  ago  as  a  2—3  year  bridge  to  transplan-
tation (BTT).  In  contrast,  western  nations  started  to  use  implantable  VADs  in  the  1980s  that
allow in-home  care  as  destination  therapy  (DT)  as  well  as  BTT.  Designated  in  2007  as  ‘‘medical
devices  in  high  demand,’’  the  5  major  implantable  mechanical  hearts  are  smoothly  undergoing
clinical  testing.  The  HeartMate  XVE  (Thoratec  Corp.,  Pleasanton,  CA,  USA)  gained  approval  from
the Ministry  of  Health  in  November  of  2009,  the  DuraHeart  (TerumoHeart,  Ann  Arbor,  MI,  USA)
and EVAHEART  (Sun  Medical,  Nagano,  Japan)  in  December  2010,  and  obtained  formal  insurance
reimbursement  in  April  2011.  The  Jarvik  2000  (Jarvik  Heart  Inc.,  New  York,  NY,  USA)  and  Heart-
Mate II  (Thoratec)  VADs  are  pending  approval.  On  the  other  hand,  the  organ  transplantation
law allowing  explantation  of  donor  organs  from  brain-dead  patients  ﬁnally  passed  in  July  2009
and was  realized  in  July  2010.  This  law  paved  the  way  to  pediatric  heart  transplants  as  well
as a  dramatic  increase  in  overall  organ  transplantation  cases.  Because  many  juvenile  patients
awaiting donor  organs  need  a  VAD  as  a  long-term  bridge,  development  and  clinical  introduction
of pediatric  VADs  capable  of  implantation  is  an  exigency.  Although  expectations  for  transplants
are high,  the  donor  numbers  are  low.  Therefore,  the  demand  for  implantable  VADs  capable  of
long-term home  treatment  is  extremely  high  in  Japan.
© 2012  Published  by  Elsevier  Ltd  on  behalf  of  Japanese  College  of  Cardiology.
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introduction
n  Japan,  the  development  of  ventricular  assist  devices
VADs)  began  in  the  1960s  [1,2], but  the  preliminary  mod-
ls  were  only  used  for  post-operative  cardiac  failure  [3].
n  those  terms,  VADs  were  not  used  as  a  ‘‘bridge  to  recov-
ry  (BTR),’’  but  as  a  temporary  measure  for  self-recovery
f  the  heart  [4—6]. It  was  not  intended  for  long-term
are  for  chronic  heart  failure  caused  by  cardiomyopathy.
ecently,  the  connotation  of  BTR  has  signiﬁcantly  changed
7—9],  as  it  now  refers  to  the  recovery  of  the  heart
hrough  various  means  of  treatment,  incorporating  surgery
10,11],  medicine  [12—14], cardiac  resynchronization  ther-
py  [15—18], apheresis  [19], and  regenerative  medicine
20,17,21], and  not  just  the  use  of  VADs.
On  the  other  end  of  the  spectrum,  the  artiﬁcial  heart
roject  that  started  in  the  USA  during  the  1960s  aimed  to
ake  a  replaceable  and  implantable  ventricular  device  that
ould  be  the  ultimate  alternative  to  heart  transplantation
22].  Because  of  this  prestigious  objective,  it  took  nearly
0  years  until  the  completion  of  AbioCor  in  2000  (Abiomed,
anvers,  MA,  USA)  (Fig.  1)  [23]. However,  in  the  realm  of
ong-term  versatility,  it  is  still  far  from  perfection.  Although
he  term  ‘‘destination  therapy  (DT)’’  insinuates  an  impec-
able  alternative  to  heart  transplantation,  because  of  the
imits  to  long-term  use  at  this  time,  it  refers  to  the  care  of
lderly  or  unﬁt  patients  that  are  not  reasonable  candidates
or  transplant  [24]. However,  if  mechanical  heart  treatment
an  surpass  the  10-year  survival  rate  for  heart  transplan-
ation,  it  is  a  reasonable  vision  that  VADs  will  be  the  most
ommon  form  of  cardiac  failure  care,  excluding  the  youth
25,26].
rtiﬁcial heart treatment in Japan
n  Japan,  VAD  treatment  started  in  1980  at  the  Mitsui
ospital  [3]  as  a  remedy  for  postcardiotomy  heart  failure
PCHF)  and  by  November  2009,  there  has  been  1128  cases
Fig.  2)  [27]. The  majority  of  those  cases  are  extracorporeal
ADs  manufactured  by  the  Japanese  company,  Nipro  (Osaka,
apan)  (Fig.  3).  The  ﬁrst  reported  case  that  a  VAD  was  used
s  a  bridge  to  transplantation  (BTT)  occurred  in  1992  at
he  Saitama  University  Medical  School  and  the  Osaka  Uni-
ersity  Hospital  for  a  patient  with  dilated  cardiomyopathy
a  Nipro  left  (L)VAD  was  used].  The  latter  case  is  the  ﬁrst
uccessful  BTT,  when  a  16-year-old  male  patient  went  from
he  University  of  Osaka  to  Texas  in  the  USA  and  endured
 150-day  bridge  period.  After  the  1997  establishment  of
he  Organ  Transplantation  Law,  heart  transplantation  also
tarted,  with  the  ﬁrst  case  occurring  in  1999  at  the  Univer-
ity  of  Osaka.  By  July  2010  before  the  revision  of  the  Organ
ransplantation  Law,  there  were  only  69  heart  transplants.
t
i
w
tnfortunately,  because  the  number  of  donors  is  severely  lim-
ted,  almost  90%  of  patients  resort  to  VADs  as  a  BTT  and
he  average  bridge  period  surpasses  800  days.  Due  to  this
act,  the  use  of  implantable  VADs  with  minimal  complica-
ions  is  imperative.  However,  only  about  20%  of  VAD  patients
urvive  the  bridge  period,  and  patients  who  continue  to
ait  for  donors  are  in  virtually  the  same  situation  as  having
eceived  DT,  even  if  the  initial  purpose  was  a  BTT.  A  majority
f  patients  with  extracorporeal  VADs  require  hospitaliza-
ion,  which  still  constitutes  DT,  but  with  a  tremendously  low
uality  of  life  (QOL).  Furthermore,  many  cardiologists  are
till  uneasy  about  DT  for  patients  who  are  not  eligible  for
ransplantation  [28,29]. On  the  bright  side,  the  successful
mplementation  of  implantable  LVADs  will  allow  patients  to
eturn  home  and  work,  raising  the  QOL.  Branching  from  this,
atients  may  be  able  to  seek  high  quality  DT  as  an  alter-
ative  to  transplantation  in  the  near  future.  Four  kinds  of
mplantable  LVAD  which  were  submitted  with  the  request
ocument  from  the  relevant  academic  societies  about  the
ighest  medical  needs,  HeartMate  XVE  (1st  generation),  EVA-
EART  (2nd  generation),  DuraHeart  (3rd  generation),  and
arvik  2000  (2nd  generation)  in  2007  and  one  more  added,
eartMate  II  (2nd  generation),  in  2011.  The  HeartMate  XVE
ained  approval  from  the  Ministry  of  Health  in  November  of
009,  the  DuraHeart  and  EVAHEART  in  December  2010  and
btained  formal  insurance  reimbursement  in  April  2011.  The
arvik  2000  and  HeartMate  II  VADs  are  pending  approval.  We
ave  treated  20  patients  with  implantable  continuous  ﬂow
VADs  (EVAHEART:  8,  DuraHeart:  8,  Jarvik  2000:  3,  HeartMate
I:  1)  (Fig.  4)  since  2007  in  the  University  of  Tokyo  Hospi-
al  and  the  clinical  outcome  of  implantable  LVADs  is  quite
ifferent  from  that  of  paracorporeal  Nipro  VAD  (Fig.  5).
mplantable VAD use in destination therapy
n  recent  years,  many  Japanese  academic  conferences  dis-
uted  the  meaning  of  DT  with  the  use  of  implantable  LVADs.
n  2008,  the  deﬁnition,  ‘‘long-term  home  treatment,’’  was
roposed  and  it  has  been  generally  accepted  ever  since
30].  In  the  past  many  total  artiﬁcial  hearts  (TAH),  such
s  the  1980  Jarvik  7  [31]  and  the  2001  AbioCor,  underwent
linical  trials  [32]  but  none  were  able  to  achieve  success
n  DT.  Rather  in  the  past  10  years,  the  use  of  implantable
VADs  in  DT  for  patients  not  eligible  for  heart  transplants
ramatically  increased.  In  the  2001  HeartMate  VE  REMATCH
tudy  (Randomized  Evaluation  of  Mechanical  Assistance  for
he  Treatment  of  Congestive  Heart  Failure)  [33], the  results
howed  that  HeartMate  VE  LVAD  treatment  excelled  over
nternal  therapy.  In  2002,  the  US  Food  and  Drug  Administra-
ion  (FDA)  approved  the  HeartMate  VE  for  DT.  Furthermore,
n  2005,  the  HeartMate  XVE  study  showed  similar  results,
hich  certiﬁed  increasing  DT  records  (Fig.  6).  In the  USA,
he  HeartMate  II  underwent  clinical  trials  for  DT  and
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mFigure  1  Totally  implantable  artiﬁcial  heart  (Ab
produced  considerably  enhanced  records  when  compared
to  the  HeartMate  XVE.  The  American  Heart  Association
(AHA)  presented  these  records  in  2009  [34]. As  a  result,  the
FDA  approved  the  HeartMate  II  for  DT  in  January  2010.
The use of destination therapy
Today’s  VAD  treatment,  like  post-operative  complications,
can  generally  be  broken  down  into  two  categories:  use  in
acute  cardiac  failure,  such  as  acute  myocardial  infarction
or  fulminant  myocarditis,  and  use  in  chronic  heart  failure,
such  as  dilated  or  ischemic  cardiomyopathy.  However,  the
line  of  distinction  is  unclear  and  is  becoming  more  and  more
perplexing.  That  is  to  say,  if  a  patient  is  diagnosed  with
acute  cardiac  failure  and  requires  a  VAD,  he  or  she  has  three
options:  (1)  Wait  for  a  heart  transplant  (BTT);  (2)  Resort  to
D
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Figure  2  Number  of  ventricular  assist  devices  in  Japan  reported  i
15th Annual  Meeting  of  the  Japanese  Association  for  Clinical  Ventric
2009).)  produced  by  AbioMed,  Inc.  (Danvers,  MA,  USA).
ong-term  VAD  use  as  a  means  to  DT;  and  (3)  Use  with  medic-
nal  treatment  or  cardiac  resynchronization  therapy  (CRT)
s  means  of  BTR  aiming  at  recovery  of  patients’  cardiac
unction.  However,  these  same  options  exist  for  patients
ith  chronic  heart  failure  (Fig.  7).  Certainly,  in  a  donor-
acking  country  like  Japan,  patients  anticipating  a  BTT  may
nd  up  receiving  DT  instead.  Likewise,  a  patient  hoping  for
 BTT  may  ultimately  achieve  a  BTR  by  self-rehabilitation.
apan  also  has  a long  average  wait  period  for  donor  hearts,
anging  from  2  to  3  years.  Therefore,  BTT  cases  require  at
east  a  2-year  VAD  treatment.  In  other  words,  VAD  treat-
ent  as  a BTT  in  Japan  requires  as  much  durability  as  a
T  device  used  in  the  USA.  Also,  because  Japan’s  current
imit  heart  transplants  to  the  age  of  59  years  and  under,
atients  who  can  potentially  receive  BTT  treatment  in  west-
rn  countries  can  only  receive  DT  in  Japan.  Unfortunately,
n  the  Japanese  registry  of  artiﬁcial  hearts  by  T.  Nakatani.  The
ular  Assist  System  (Toki  Messe:  the  Niigata  convention  center,
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(igure  3  Nipro  left  ventricular  assist  device  (LVAD)  system.  L
riving console  VCT-50.
he  lack  of  Japanese  evidence  showing  LVAD  DT  predomi-
ance  over  internal  therapy  makes  it  difﬁcult  for  patients
o  receive  ﬁnancial  reimbursement.  In  Japan,  circulatory
nternal  therapy  has  many  ways  of  treatment,  including  CRT-
eﬁbrillator,  intra-aortic  balloon  pump,  or  percutaneous
ardiopulmonary  support.  Because  of  this,  VADs  were  only
sed  for  patients  with  Stage  D  cardiac  failure  (Table  1).  It
as  considered  to  be  a  ﬁnal  procedure  rather  than  a  routine
ne.  Therefore,  the  reality  is  that  there  is  little  data  that
ccurately  VAD  records.  However,  using  a  VAD  for  patients
ith  Stage  D  cardiac  failure  makes  a  bias  point  on  the
ecords  because  the  chances  of  recovery  are  slim.  Recently
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igure  4  Four  kinds  of  implantable  left  ventricular  assist  device
elevant academic  societies  about  the  highest  medical  needs,  HeartM
TerumoHeart),  and  Jarvik  2000  (Jarvik  Heart  Inc.).LVAD  mounted  on  anatomical  model  of  the  human  body.  Right:
n western  nations,  a  bridge  to  decision  (placing  a  tempo-
ary  VAD  in  a  patient  and  waiting  for  recovery  until  further
ction)  has  become  increasingly  popular  [35,36]  due  to  its
nancial  affordability.
VAD destination therapy and future prospectsn  November  2009,  the  AHA  presented  the  results  of  the
eartMate  II  Destination  Therapy  Trial.  This  trial  consisted  of
ata  contrasting  the  ﬁrst-generation  pulsatile  pump  Heart-
ate  XVE  (PF  VAD)  and  the  second  generation,  continuous
 which  were  submitted  with  the  request  document  from  the
ate  XVE  (Thoratec  Corp.),  EVAHEART  (Sun  Medical),  DuraHeart
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Figure  5  Clinical  outcome  of  left  ventricular  assist  device
(VAD) therapy  in  the  University  of  Tokyo  Hospital  since  2007.  The
Figure  7  The  target  of  treatment  by  implantable  left  ven-
tricular  assist  device  (LVAD)  is  to  control  heart  failure  at  home
and regain  social  activities  for  a  patient  who  is  depending  on
cathecholamine  in  hospital.  The  goal  of  implantable  LVAD  ther-
apy can  be  heart  transplant  (BTT),  recovery  of  the  function  of
native heart  (BTR),  or  life-prolonging  treatment  (DT,  destination
therapy).  In  Japan  the  heart  transplant  is  restricted  extremely,
and we  should  consider  it  to  be  second  guessing  whether
t
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pclinical  outcome  of  implantable  continuous  ﬂow  VADs  is  quite
different  from  that  of  paracorporeal  Nipro  VAD.
ﬂow  HeartMate  II  (CF  VAD)  [34]. The  HeartMate  II  pump  was
roughly  1/5  the  size  and  1/3.5  the  weight  of  the  Heart-
Mate  XVE.  It  allowed  easier  implantation  for  use  on  smaller
patients.  Most  importantly,  this  trial  showed  the  HeartMate
II’s  superiority  over  the  predecessor  in  terms  of  2-year  sur-
vival  rate.  The  HeartMate  II  managed  a  46%  (62/134)  survival
rate  at  24  months,  free  from  disabling  stroke  or  re-operation
for  device  replacement  (intention-to-treat)  versus  an  11%
(7/66)  rate  for  the  HeartMate  XVE.  Because  the  134  patients
with  the  HeartMate  II  were  all  in  critical  condition,  either
due  to  their  age,  body  mass,  diabetes,  high  blood  pressure,
renal  failure,  or  recent  migrant  tumors,  the  46%  survival  rate
free  from  major  complications  was  extraordinary.  The  aver-
age  age  of  these  patients  was  62—63  years  old  and  over
t
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Figure  6  Survival  curve  reported  in  REMATCH  study  (Heart  Mate  
Therapy Trial.  HeartMate  II  showed  signiﬁcant  higher  survival  rate  ahe goal  is  BTT,  BTR,  or  DT.  CRT,  cardiac  resynchronization
herapy.
/3  had  ischemic  cardiomyopathy  with  20%  experiencing
rain  complications.  The  studies  on  post-operative  compli-
ations  also  showed  that  many  suffered  renal  failure,  pump
xchanges,  infections,  cardiac  arrhythmia,  and  breathing
roblems  (Fig.  8).  Perhaps  above  all,  the  pump  complica-
ions  1—2  years  after  implantation,  HeartMate  XVE’s  largest
rawback,  dropped  sharply  (0.06/year  vs.  0.51/year),  and
eartMate  II’s  pump  exchange  rate  decreased  to  6  cases  out
f  every  100  VADs.  In  January  2010,  the  HeartMate  II  was
XVE  Destination  Therapy  Trial)  and  Heart  Mate  II  Destination
t  two  years  over  HeartMate  XVE  [35,36].
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Table  1  Inclusion  and  exclusion  criteria  for  implantable  LVAD.
Disease  and  morbidity
End  stage  heart  failure  requires  heart  transplantation  including  dilative  cardiomyopathy,  dilative  phase  of  hypertrophic
cardiomyopathy,  ischemic  cardiomyopathy,  valvular  heart  disease,  congenital  heart  disease,  and  cardiomyopathy  following
myocarditis.
Inclusion criteria
Cardiac  function NYHA:  Class  III—IV  (Past  history  of  Class  IV)
Stage Stage  D  (patient  with  end-stage  disease  who  is  frequently  hospitalized  for  chronic  heart
failure or  who  requires  special  treatments  such  as  LVAD,  artiﬁcial  heart,  ionotropic
infusions,  heart  transplant  or  hospice  care)
Medication  Patient  already  receiving  maximal  medical  treatment  with  digoxin,  diuretics,
angiotensin-converting  enzyme  inhibitor,  angiotensin  receptor  blocker,  nitrates,
-blocker
Catecholamine  and  assist
circulation
Depending  on  dobutamine,  dopamine,  epinephrine,  norepinephrine,  phosphodiesterase
III inhibitor,  or  intra-aortic  balloon  pump,  extracorporeal  ventricular  assist  device
Age Under  65  years  is  desirable  (depending  on  physical  strength,  it  takes  aged  65  and  over
into consideration)
Body surface  area  A  system  prescribes  individually
Hemodynamics  Stage  D,  past  history  of  NYHA  Class  IV
Condition The  patient  in  which  high  QOL  can  be  obtained  by  participating  in  medical  treatment,
can perform  long-term  home  treatment,  and  can  expect  social  rehabilitation  by  the
patient to  whom  the  prolongation  of  life  could  not  be  expected  under  other  medical
treatment  and,  to  whom  the  obstacle  of  the  QOL  was  carried  out  remarkably
Patient understanding She/he  understands  the  limit  and  complications  of  an  assisted  artiﬁcial  heart,  and  an
understanding  and  support  of  a  family  are  obtained
Exclusion  criteria
Infection  Serious  infection
Respiratory  ailment  Serious  chronic  obstructive  pulmonary  disease
Advanced  pulmonary  hypertension
Pulmonary  artery  embolism  whose  symptoms  were  shown  within  30  days
Cardiovascular  disease  The  early  stage  after  open  heart  surgery  (about  two  weeks)
The abdominal  aneurysm  and  the  serious  peripheral  vascular  disease  which  cannot  be
treated
Thoracic aortic  aneurysm,  left  ventricular  aneurysm,  ruptured  interventricular  septum
Aortic insufﬁciency  more  than  moderate  degree
Calciﬁcation  critical  in  the  thoracic  aorta
Neuropathy  Serious  damage  in  the  central  nervous  system
Drug  intoxication  or  the  past  history  of  alcohol  dependence
A psychoneurotic  disorder  or  it  is  not  followed  to  a  protocol,  to  the  extent  that  it  is
judged that  an  understanding  is  impossible
Other organ  disease  Systemic  diseases,  such  as  serious  hepatic  disease,  serious  bleeding  tendency,  advanced
chronic  renal  failure,  hemodialysis  patient  due  to  chronic  renal  failure,  and  virulent
disease with  poor  life  prognoses  such  as  cancer,  collagen  disease,  and  insulin  dependent
diabetes
Pregnancy Under  pregnancy
Others  The  case  judged  unsuitable  by  the  institutional  review  board,  such  as  remarkable
overweight  and  transfusion  refusal.
LVAD, left ventricular assist device; NYHA, New York Heart Association; QOL, quality of life.
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ue  to  the  expensive  price,  VADs  in  the  USA  can  cost  over
150,000  including  the  surgery  fee,  the  use  of  LVADs  for
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bT  has  been  strictly  controlled.  In  the  early  periods  of
VADs,  the  hospital  and  insurance  company  had  contracts
hat  were  in  favor  of  the  insurance  company.  Therefore,
ospitals  had  to  be  prepared  for  a  fairly  large  ﬁnancial  loss
hen  they  installed  LVADs  [37,38].  In  Japan,  Novacor  (Rueil-
almaison,  France)  was  approved  by  insurance  agencies  as
TT  appropriate  in  2004.  However,  due  to  the  fact  that  the
ld  model  was  approved  and  cost  a  large  sum  to  exchange
atteries,  the  manufacturer  could  not  maintain  use  of  the
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Figure  8  Comparison  of  two-year  event-free  survival  rate  (free  from  death,  disabling  stroke,  or  re-operation  for  device  replace-
ment) between  CF  LVAD  and  PF  LVAD.  Signiﬁcant  superiority  of  CF  LVAD  in  two-year  event-free  survival  rate  (46%  vs.  11%)  [36].  CF,
le  ﬂo
acontinuous ﬂow;  LVAD,  left  ventricular  assist  device;  PF,  pulsati
product  and  dropped  out  of  the  competitive  market  in  2
years.  Japanese  academic  societies  have  repeatedly  asked
for  insurance  reimbursements  for  device  maintenance  past
91  days  for  implantable  LVADs.  This  time,  in  regards  to  the
EVAHEART  and  DuraHeart  VADs’  manufacturers’  approval
m
t
s
l
Figure  9  Changes  of  insurance  reimbursement  of  the  HeartMate
Medicare in  the  USA.  Although  it  was  a  little  less  than  40,000-dolla
VE was  recognized,  insurance  reimbursement  was  increased  to  almo
(Thoratec data;  2009/2010  Reimbursement  Overview:  HeartMate  II.)w.
nd  insurance  reimbursements,  the  academic  society’s
ain  concern  is  that  those  new  regulations  do  not  shape
he  Japanese  market  for  implantable  LVADs  [39]. Without  a
tructured  market,  implantable  LVADs  will  disappear,  much
ike  the  Novacor  VAD.  Furthermore,  patients  waiting  for
 left  ventricular  assist  device  (LVAD)  implantation  surgery  by
r  reimbursed  in  2002  when  destination  therapy  by  Heartmate
st  200,000  dollars  in  2010  when  HeartMate  II  was  recognized.
 CMS,  US  Centers  for  Medicare  and  Medicaid  Services.
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onor  hearts  will  be  forced  to  have  extracorporeal  VADs  and
ospitalization.  Hospitals  will  also  suffer  because  patients
ho  stay  for  an  extended  period  of  time  do  not  increase
roﬁts.  Extended  stay  also  points  to  the  unsolved  problem
f  hospital  room  overcapacity.  The  current  revision  provides
eimbursement  for  pump  device  of  18,100,000-yen,  and  for
ver  91  days  and  a  monthly  245,000-yen;  however,  even  with
his  revision  BTT  cost  for  3  years  can  be  reduced  about  49%
ith  CF  LVAD  from  that  with  Nipro  VAD  [40]. From  now  on,
any  experts  anticipate  that  manufacturers  will  not  expe-
ience  a  deﬁcit  and  a  structured  market  will  soon  appear.
n  the  other  hand,  the  implantable  VADs  for  DT  (2002)  were
pproved  by  the  US  Centers  for  Medicare  and  Medicaid  Ser-
ices  (CMS)  and  the  annual  reimbursement  levels  increased
onsiderably  from  $40,000  and  under  to  $196,000  in  2009
Fig.  9).  Especially,  the  HeartMate  II  implantation  surgery
t  teaching  hospitals  received  $290,000,  which  indicates
‘high  quality  medical  care’’  for  that  medical  institution.
linical  effectiveness  and  medical  costs  should  correlate
ith  one  another  in  a  capitalistic  economy  through  market
heory.  By  initiating  that  correlation,  the  competitive  race
o  manufacture  high  quality  medical  devices  ﬁnally  begins
41—43].  Also,  this  motivation  for  higher  achievement  is
ital  to  Japan’s  medical  device  industry.
onclusion
n  Japan,  the  fact  that  an  extracorporeal  VAD  developed
0  years  ago  that  gained  approval  30-day  use  and  medi-
al  reimbursement  for  acute  heart  failure  in  1994  which
as  not  permitted  for  BTT  use  until  2006,  being  used  as
 2—3  year  BTT  is  complete  nonsense.  Not  only  does  forcing
ong-term  hospitalization  during  the  bridge  period  signiﬁ-
antly  reduce  patient  QOL,  but  it  also  limits  the  hospital’s
roﬁt  due  to  the  lack  of  open  beds  for  new  patients.  Sup-
orting  hospitalization  for  over  20  patients  with  VADs  is  an
xtreme  burden  on  the  hospital  and  two-thirds  of  them  are
ot  able  to  receive  a  donor  organ.  In  summary,  the  lack  in
uality  and  quantity  of  VADs  has  been  solely  caused  by  gov-
rnment  administrations.  In  developed  nations  such  as  the
SA,  patients  are  allowed  to  recover  at  home  as  a  BTT  or
T.  In  contrast,  the  current  regulation  in  Japan  severely  lim-
ts  the  number  of  VAD  patients.  Is  this  something  that  can
e  overlooked?  As  Japan  attempts  to  provide  everyone  with
air  medical  care,  in  reality,  the  administration  is  restrain-
ng  patients  with  30-year-old  VADs  in  hospitals  until  they
ither  receive  a  donor  heart  or  pass  away.  There  is  deﬁ-
itely  a  need  to  clearly  say  that  something  is  wrong.  The
linical  trials  for  the  5  major  implantable  LVADs  designated
n  2007  are  going  smoothly.  The  ﬁrst  end  point  observation
6  months  after  implantation)  has  been  completed  and  the
eartMate  XVE  was  approved  in  November  2009,  the  Dura-
eart  and  EVAHEART  in  December  2010;  Jarvik  2000  and  the
eartMate  II  are  pending  approval.  In  contrast,  the  regula-
ions  for  heart  transplants  are  more  than  10  years  behind.
he  new  organ  transplant  law  passed  in  July  2009.  There
s  much  anticipation  that  this  new  law  will  carve  the  way
or  pediatric  organ  transplants.  Since  minors  have  a  high
emand  for  long-term  LVADs  due  to  the  extended  bridge
eriod,  new,  improved  VADs  are  needed  more  than  they
ver  were.
[S.  Kyo  et  al.
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